Do analysts prefer SCLX or CTXR?

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 637.46%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings and valuation, DWTX or CTXR?

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is DWTX or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Citius Pharmaceuticals N/A -61.09% -35.36%

Does the media refer more to DWTX or CTXR?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 3 articles in the media. Dogwood Therapeutics' average media sentiment score of 0.37 beat Citius Pharmaceuticals' score of 0.34 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INCR or CTXR?

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 637.46%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is INCR or CTXR more profitable?

InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Citius Pharmaceuticals N/A -61.09% -35.36%

Which has better valuation & earnings, FLNA or CTXR?

Cassava Sciences is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is FLNA or CTXR more profitable?

Cassava Sciences' return on equity of -58.78% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Citius Pharmaceuticals N/A -61.09% -35.36%

Does the media favor SCYX or CTXR?

In the previous week, SCYNEXIS had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for SCYNEXIS and 3 mentions for Citius Pharmaceuticals. SCYNEXIS's average media sentiment score of 0.72 beat Citius Pharmaceuticals' score of 0.34 indicating that SCYNEXIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Citius Pharmaceuticals (CTXR) Competitors

$0.68 -0.01 (-0.92%)

As of 01:44 PM Eastern

Compare

CTXR vs. SCLX, DWTX, INCR, FLNA, and SCYX

Should you buy Citius Pharmaceuticals stock or one of its competitors? MarketBeat compares Citius Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Pharmaceuticals include Scilex (SCLX), Dogwood Therapeutics (DWTX), InterCure (INCR), Cassava Sciences (FLNA), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceuticals" industry.

How does Citius Pharmaceuticals compare to Scilex?

Scilex (NASDAQ:SCLX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Citius Pharmaceuticals has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

Citius Pharmaceuticals has lower revenue, but higher earnings than Scilex. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$33.86M	1.71	-$358.73M	-$40.47	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Scilex has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

69.7% of Scilex shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 4.5% of Scilex shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 0 mentions for Scilex. Citius Pharmaceuticals' average media sentiment score of 0.34 beat Scilex's score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Scilex	Neutral
Citius Pharmaceuticals	Neutral

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 637.46%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Citius Pharmaceuticals beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Dogwood Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Dogwood Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 581.82%. Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 637.46%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Citius Pharmaceuticals' return on equity of -61.09% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 3 articles in the media. Dogwood Therapeutics' average media sentiment score of 0.37 beat Citius Pharmaceuticals' score of 0.34 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Dogwood Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to InterCure?

InterCure (NASDAQ:INCR) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

InterCure has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.68	-$10.37M	$0.03	32.37
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

InterCure has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 0 mentions for InterCure. Citius Pharmaceuticals' average media sentiment score of 0.34 beat InterCure's score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Citius Pharmaceuticals	Neutral

Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 637.46%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

8.3% of InterCure shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

InterCure and Citius Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Cassava Sciences' return on equity of -58.78% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Cassava Sciences. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 0 mentions for Cassava Sciences. Citius Pharmaceuticals' average media sentiment score of 0.34 beat Cassava Sciences' score of 0.00 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cassava Sciences	Neutral
Citius Pharmaceuticals	Neutral

Cassava Sciences presently has a consensus price target of $5.00, suggesting a potential upside of 387.80%. Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 637.46%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cassava Sciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Cassava Sciences is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.

How does Citius Pharmaceuticals compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

SCYNEXIS has higher revenue and earnings than Citius Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.34M	2.53	-$8.61M	-$3.84	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by company insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Citius Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

In the previous week, SCYNEXIS had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for SCYNEXIS and 3 mentions for Citius Pharmaceuticals. SCYNEXIS's average media sentiment score of 0.72 beat Citius Pharmaceuticals' score of 0.34 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SCYNEXIS presently has a consensus target price of $24.00, indicating a potential upside of 363.32%. Citius Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 637.46%. Given Citius Pharmaceuticals' higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

SCYNEXIS has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Summary

SCYNEXIS beats Citius Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTXR vs. The Competition

Export

Metric	Citius Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.61M	$11.92B	$7.04B	$12.92B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.32	788.54	269.97	24.82
Price / Sales	N/A	967.38	650.66	108.09
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.16	10.33	11.26	6.44
Net Income	-$37.43M	$2.77B	$3.45B	$347.27M
7 Day Performance	13.76%	1.99%	3.62%	2.55%
1 Month Performance	16.35%	-1.56%	-0.56%	-1.02%
1 Year Performance	-44.88%	191.17%	77.38%	23.33%

Citius Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTXR Citius Pharmaceuticals	2.3851 of 5 stars	$0.68 -0.9%	$5.00 +639.6%	-44.5%	$18.58M	N/A	N/A	20	News Coverage Upcoming Earnings
SCLX Scilex	0.2636 of 5 stars	$6.56 -1.5%	N/A	-55.8%	$56.59M	$33.86M	N/A	80
DWTX Dogwood Therapeutics	2.983 of 5 stars	$1.71 +4.3%	$12.00 +601.8%	-62.6%	$55.15M	N/A	N/A	5	Upcoming Earnings
INCR InterCure	1.206 of 5 stars	$0.98 +1.5%	N/A	-34.7%	$52.59M	$78.47M	32.53	350	Gap Down
FLNA Cassava Sciences	1.5024 of 5 stars	$1.03 +2.0%	$5.00 +385.4%	-54.4%	$48.79M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTXR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. SCLX, DWTX, INCR, FLNA, and SCYX

How does Citius Pharmaceuticals compare to Scilex?

Summary

How does Citius Pharmaceuticals compare to Dogwood Therapeutics?

Summary

How does Citius Pharmaceuticals compare to InterCure?

Summary

How does Citius Pharmaceuticals compare to Cassava Sciences?

Summary

How does Citius Pharmaceuticals compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Pharmaceuticals (CTXR) Competitors

CTXR vs. SCLX, DWTX, INCR, FLNA, and SCYX

How does Citius Pharmaceuticals compare to Scilex?

Is SCLX or CTXR more profitable?

Which has better earnings & valuation, SCLX or CTXR?

Which has more volatility & risk, SCLX or CTXR?

Do insiders & institutionals have more ownership in SCLX or CTXR?

Does the media refer more to SCLX or CTXR?

Do analysts prefer SCLX or CTXR?

Summary

How does Citius Pharmaceuticals compare to Dogwood Therapeutics?

Which has higher earnings and valuation, DWTX or CTXR?

Which has more volatility & risk, DWTX or CTXR?

Do analysts rate DWTX or CTXR?

Is DWTX or CTXR more profitable?

Does the media refer more to DWTX or CTXR?

Do institutionals & insiders have more ownership in DWTX or CTXR?

Summary

How does Citius Pharmaceuticals compare to InterCure?

Which has better earnings & valuation, INCR or CTXR?

Is INCR or CTXR more profitable?

Which has more risk & volatility, INCR or CTXR?

Does the media refer more to INCR or CTXR?

Do analysts recommend INCR or CTXR?

Do insiders and institutionals hold more shares of INCR or CTXR?

Summary

How does Citius Pharmaceuticals compare to Cassava Sciences?

Is FLNA or CTXR more profitable?

Does the media favor FLNA or CTXR?

Do analysts prefer FLNA or CTXR?

Which has more volatility and risk, FLNA or CTXR?

Which has better valuation & earnings, FLNA or CTXR?

Do insiders and institutionals hold more shares of FLNA or CTXR?

Summary

How does Citius Pharmaceuticals compare to SCYNEXIS?

Which has higher valuation & earnings, SCYX or CTXR?

Do insiders and institutionals have more ownership in SCYX or CTXR?

Is SCYX or CTXR more profitable?

Does the media favor SCYX or CTXR?

Do analysts recommend SCYX or CTXR?

Which has more risk & volatility, SCYX or CTXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR vs. The Competition

Citius Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools